INTRODUCTION
Hepatocellular carcinoma (HCC) is an important disease with worldwide distribution. It can cause death to affected patients through massive tumor extension or by liver failure. The etiology of HCC is different among different geographic areas. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Even among Asian countries, the proportion of viral etiology is different, with hepatitis C virus (HCV) is playing a major role in Japan, whereas hepatitis B virus (HBV) predominates in other Asian countries. [1] [2] [3] [4] [5] The mode of diagnosis and treatment is also different among different countries.
In this working report, by combining patient data files at the onset of the disease from several participating countries and by comparing clinical profiles, we tried to determine characteristic features of HCC from different countries.
The diagnostic and therapeutic modalities for HCC have improved dramatically in recent years. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Therefore, there is an immediate need to establish standard criteria that can be used worldwide to estimate disease progression. For 15 years the Okuda staging system has been used to predict the prognosis of HCC. 21 However, it has become somewhat obsolete considering the remarkable advance of the present status of diagnosis and treatment of HCC. Several staging systems have been proposed recently. [22] [23] [24] Thus, in this working report we applied various staging systems on a given population of patients, and tested their prognostic value. the patients with the same CLIP score were compared between Japan and Italy. Survival information was analyzed by the Kaplan-Maier method and significance was tested by the log-rank test.
'Tokyo' score
In addition, we tried to design a new scoring system ('Tokyo' score) by using data obtained from a larger number of patients; a series of 403 HCC patients admitted and treated in Tokyo University during 1990-1997 1, 11, 26 as 'training' cases. Cox proportional hazard model was applied to the 403 cases, and univariate and multivariate analysis was performed. Factors with significant and independent hazards were picked up and a new scoring system was created. We arbitrarily call this 'Tokyo' scoring system.
Comparison of three scoring systems as prognostic indices of HCC
Okuda staging, CLIP and 'Tokyo' system were applied to the 403 Japanese patients, as sufficient data on patient survival were available from these patients. Prognosis-discriminant ability of the three scoring systems were compared.
A dataset of 336 Thai HCC patients from Dr Teerha Piratvisuth in Thailand, and data files of 80 German HCC patients from Drs Karl Lenhard Rudolph and Michael Manns, Hannover, were used in some instances as appropriate.
All statistical analyses were executed by STATVIEW version 5.0 software (Windows version, SAS Institute Inc., Cary, NC, USA).
Creation of an international mailing list
For this working party, we created an international mailing list. The mailing list was run by 12 members in a closed circle (four from Japan, three from Thailand, three from Italy, one from Germany and one from Taiwan). The mailserver machine is located in UMIN (University Hospital Medical Information Network, Japan, URL: http://www.umin.ac.jp/eng/), a cooperative organization for national medical schools in Japan. Patient data submission and exchange of necessary information and discussion were all held on the mailing list.
RESULTS

Diversity of etiology
Of the 115 Japanese, 51 Thai, and 103 Italian patients, males comprised 65, 91 and 81% in Italy, respectively (Table 1) . Average age of onset of the disease is around 63 years old in Japan, 56 years in Thailand, and 65 years in Italy (Table 1 ; Fig. 1 ). Age distribution patterns are almost identical between Italy and Japan (Fig. 1) . However, in Thailand, people develop HCC in their thirties and forties and sometimes even in their twenties (Fig. 1) .
Positivity of (hepatitis B surface (HBs) antigen is 10% in Japan, 61% in Thailand, and 17% in Italy (Table  1) . In contrast, anti-HCV antibody is positive in 83% in Japan, only 28% in Thailand, and 89% in Italy. Again, the infection pattern is similar between Italy and Japan, namely, a large population of HCC are derived from hepatitis C virus infection in these two countries. In contrast, most Thai HCC is caused by hepatitis B virus infection.
Hepatocellular carcinoma was found during follow up of chronic liver disease in 38% of patients in Japan, while only 9% in Thailand (data not shown). No data available for Italy. 
Liver function tests
As for liver function tests, distribution of Child-Pugh classification was comparable among the three countries (50-60% in Child A, 14-31% in Child B, and 11-22% in Child C) ( Table 1) . Distribution of serum alanine aminotransferase (ALT) values was also comparable among the three countries (Fig. 2) . However, in Thailand, some patients exhibited extremely high aspartate aminotransferase (AST) values (over 200 IU/ mL) ( Fig. 2 ) and platelet counts (over 300 000/mm 3 , data not shown). Such patients also have large tumor size, and are generally positive for hepatitis B virus.
Tumor size, number and extension
Average diameter of tumor nodule with maximal size in each patient is 3.3 ± 1.9 cm (Japan), 9.8 ± 7.3 cm (Thailand) and 4.4 ± 3.2 cm (Italy) (Table 1; Fig. 3 ).
The tumor nodules from patients with HCC in Japan and in Italy show a single peak of sizes, and similar distribution pattern (Fig. 3) . In contrast, there is a wide range of distribution of tumor size in Thailand (Fig. 3) .
Frequency of portal vein tumor thrombosis at the onset of the disease is 6% in Japan, 29% in Thailand, and 5% in Italy (Table 1) . It seems there is not much difference in the number of cancer nodules between patients from these countries (Fig. 4) .
These data clearly indicate that Japan and Italy again showed a similar pattern of tumor size, number and extension compared with Thailand.
Treatment modalities
In the University of Tokyo Hospital, 87% of the patients were first treated by local ablation therapy including percutaneous ethanol injection treatment (PEIT) and microwave coagulation (PMCT), which accomplished nominally 'curative' therapeutic effect. 11, 26 In Thailand, most patients were treated by transarterial embolization therapy, chemotherapy or by both (Table 1 ). In Italy there was a balanced distribution of treatment modalities, half by local ablation therapy and others by surgical resection or by transarterial chemoembolization (TACE) ( Table 1) .
Application of CLIP score to 115 Japanese and 103 Italian patients
In order to 'test' the scoring system to predict the prognosis proposed by different authors, 21, 22 we first applied the CLIP scoring system to our 115 Japanese and 103 Italian patients because sufficient data regarding patient survival were available from the two countries.Thai survival data could not be used at this time because of the short observation period and data collection.
Regarding the average length of survival of HCC patients in the two countries, 75% and 50% survival times were 954 days and 1721 days in Japan, and 374 days and 864 days in Italy, respectively. Stratification of patients was performed by CLIP score (Table 2) . Distribution profiles of CLIP score at the onset of disease were similar between Japan and Italy ( Table 1) . The patients were evenly distributed between score 0-2, less patients with score 3, and few patients with higher scores both in Italy and Japan (Table 1) .
To 'test' the prognosis-discriminating ability of the CLIP score, survival was analyzed by the Kaplan-Maier method (Fig. 5) . CLIP score showed good prognosisdiscriminating ability in both countries (Fig. 5) . We also examined the difference, if any, of length of survival in Italy and Japan, according to the Score by CLIP (Fig.  6 ). Japanese patients, on average, seem to survive longer than Italian patients for each CLIP score class (Fig. 6) . However, to test the prognosis-discriminating ability further, the number of HCC patients is too small.Thus, we obtained data from our 403 Japanese HCC patients, and analyzed the following.
Application of three scoring systems (Okuda, CLIP and 'Tokyo') to Japanese patients
To conduct further evaluation of the scoring systems (Okuda, CLIP, and 'Tokyo') ( Table 2) , we analyzed a larger number of patients, 403 Japanese patients from our data (Table 3) . Okuda staging system, CLIP score and 'Tokyo' scoring system were applied to these patients and the patients were classified into groups (Table 4) . Distribution profile and median survival of each group is shown (Table 4 ). By Okuda's scoring, most of our cases (94%) were grouped into stage I. There were few cases (6%) with stage II, and none with stage III (Table 4) . As for CLIP score, there was a balanced distribution within score 0-2, with a few cases in score 3 (4%), however, none above score 4 (Table 4 ). Using the 'Tokyo' score, Japanese patients were distributed from score 0-7, and mean survival period decreased accordingly (Table 4) . Regarding the prognosis-discriminating ability of the three systems, Okuda staging could give us very limited information and separation between stages I and II seems 'narrow' (Fig. 7) . CLIP and 'Tokyo' were capable of predicting prognosis with orderly and excellent discrimination for this population (Fig. 7) .
DISCUSSION
Different presentation of HCC among different countries
This is not a comprehensive study involving multiple centers from individual country. The patient number is limited, only about 100 per nation. Treatment modalities are also unbalanced between institutions. Thus patients in this study may not necessarily represent average HCC patients of their respective nations. Nonetheless, both characteristic features of HCC presentation from each country and existence of common property of HCC irrespective of nationality are evident from these limited data files.
Patients from Japan and Italy share comparable distributions of sex, age, viral profiles and, accordingly, tumor extension. But there is a remarkable difference in profiles of age, tumor size and transaminase values between Thailand and the other two countries.This may originate from different ways of ambulatory follow up of cirrhotic patients. But the most important difference is that in Thailand a significant proportion of HCC is derived from HBV infection. [2] [3] [4] [5] This may explain the younger age of HBV-related HCC in Thai patients. Although Thai patients with HCC are relatively young, they still may have had 30-40 years of continuous inflammation and necrosis after the vertical transmission, which might be sufficient to develop cirrhosis and eventual HCC at early ages. In additon, in HBV infection, some patients develop HCC without cirrhosis as Italian and Japanese patients present almost the same profile of liver function and tumor extension. All these similarities stem from the fact that 70-80% of HCC are due to HCV infection (Table 1) . This is quite a contrast to HBV-predominant Thailand.
As clinical characteristics of HCC are similar and the distribution profile of the scoring system, for example, CLIP score, are almost identical between Japan and Italy, it might be fair to compare the survival of HCC patients of the two countries. Japanese patients exhibited better survival than Italian patients for each CLIP score class (Fig. 6) . The reason is not clear at this time. It may be due to racial difference, mode of ambulatory observation, supportive therapy for chronic liver disease, or skill of treatment. It is of particular interest to explore the reason for the difference of survival between two countries.
The German data files have been submitted recently from Drs Rudolph and Manns, and detailed analysis is not feasible at this time. But the preliminary observation is interesting and as follows.
B-viral, C-viral, and alcoholic etiologies share comparable proportions.
This is in contrast to other countries. Also, complication of ascites and esophageal varix is fairly frequent, and maybe related to alcoholic origin.
There are very few purely alcoholic cirrhosis and HCC in Japan. Comparison between Japan and Germany might be interesting to elucidate the difference between alcohol and viral origin HCC.
Our current preliminary result of Working Party clearly suggests: three major worldwide etiologies of HCC (HBV, HCV, and alcohol) may play roles, but with different symptoms. The difference in clinical presentation and even symptoms may be strongly influenced by the etiologies in different countries, like Italy, Japan and Germany. However, in developing countries, other factors and socioeconomic status influences the 'pictures' of HCC.
For world-standard scoring system
The Okuda scoring system is invalid for 403 patients from Tokyo University, because most patients were included in stage I. There were only 16 patients (4%) at stage II and none at stage III.
Besides the distribution profile of each score, the quality of this kind of scoring system is judged by its prognosis-discriminatory ability. Both CLIP and 'Tokyo' scoring systems showed good resolution of prognosis for patients from Tokyo University. It is now to be tested for 80 German and an additional 336 Thai patients from Dr Teerha Piratvisuth.
As for CLIP score, Japanese patients are evenly distributed between zero to three with good resolution ability. It appears there is little difference between the CLIP and 'Tokyo' scoring systems. However, the 'Tokyo' scoring system could isolate a group with excellent prognosis ('Tokyo' 0, 54 of 399 patients). In fact, the 3-year survival of the 54 patients is 90% and median survival reaches 7.4 years ( Table 4) . sometimes seen in teenagers, suggesting HBV might have carcinogenic properties of its own that differ from that of HCV.
In contrast, HCV-derived liver disease takes a fairly constant course, that is, low grade but long-lasting inflammation and necrosis, and subsequent fibrosis and eventual cirrhosis and HCC. 1, 27 Thus, it is easier to set high risk group, and by ambulatory follow up we can find small HCC nodules. Regarding scores related to tumor character, Okuda's staging may need modification (Table 2) . Nowadays, most hospitals may make a diagnosis of HCC with ultrasound, CT, MRI and other precise measures to detect exact size and number of cancer nodules. It appears, however, that Okuda's classification on tumor morphology is primarily derived from the knowledge of autopsy gross findings. Thus, tumor classification and scores could be updated, and there is a lot of room to revise the scoring system for tumor category, especially for small HCC.
Inclusion of Child-Pugh classification into this kind of scoring system is indispensable and differences among scoring system might be small. Child-Pugh classification sets two cut-off points of 2.8 and 3.5 g/dL for albumin, and also two cut-off points of 2.0 and 3.0 mg/dL for total bilirubin.The Okuda staging system has only one cut-off point for each; 3.0 g/dL for albumin and 3.0 mg/dL for total bilirubin. Thus, we may need some small adjustment to obtain consensus on the evaluation of 'background' liver function.
The recent report on 662 Japanese patients from Kagoshima University confirmed the excellent prognosis-discriminating ability of the CLIP system, 28 suggesting CLIP score could be used in both countries (Japan and Italy) because of similarities in many aspects related to HCC in Japan and Italy. However, what about other geographic areas, for example, in areas where HBV infection prevails? Regarding this, a larger number of patients from Thailand could be analyzed and Dr DS Chen of National Taiwan University will submit their cases for analysis.
The criteria set by Italian (CLIP) and Japanese ('Tokyo') patients are from patients with relatively early and small HCC. Thus, CLIP and 'Tokyo' scoring systems may not have better a resolution ability for advanced tumor extension. Instead, it may be useful in comparing local ablation therapy and hepatic resection, both of which are executed in cases with earliest tumor extension. Certainly, we need to test the scoring systems in countries where more advanced cases are seen more often. We will test the 336 cases recently sent from Thailand by Dr Teerha Piratvisuth by the time of this Working Party report in Bangkok.
Even the group with supposed excellent prognosis ('Tokyo' score zero group), the survival gradually decreases after 3 years with no better survival in the 7-10-year range than more unfavorable cases (Fig. 7) . This suggests an eventually fatal nature of this terrible malignancy.
Fifteen years have passed from Okuda's milestone paper. 21 Diagnostic and therapeutic methods have changed dramatically since then. [11] [12] [13] [14] [15] [16] [17] [18] [19] For this reason it has become necessary to establish clinical indices with a high predicting ability such as a CLIP score suitable for the present times. Candidates of newer parameters will be shown in the Working Party. Validity of such parameters, besides more conventional indices, will be tested in many institutions and many countries.
It is becoming more and more difficult to establish appropriate prospective randomized trials. Because patients with this malignancy cannot be left untreated, the natural history (prognosis without treatment) of HCC will never be known, especially the small and treatable ones. In addition, a whole battery of treatment including locoregional, transarterial, and surgical treatment modalities adds another bias.
Prognosis-discriminating score per se does not indicate which therapy to take for a specific patient. We know that we cannot compare treatment effect or survival outcomes in this dataset. We may have to be content to produce surrogate comparisons. But we believe that such effort to standardized HCC staging is definitely needed to help compare the ability to diagnose and, more importantly, the ability to treat HCC in different countries.
CONCLUSION
Patients in this study come from one or two institutions per nation, so may not represent average HCC patients of its nation. Nonetheless, both characteristic features of HCC presentation from each country and existence of common property of HCC irrespective of nationality can be assumed.
It has become necessary to establish an HCC staging system that is more suitable than the Okuda staging system for separating earlier stages of HCC. Stratification study between different countries and between different methods of treatment will be possible by such scoring systems.
Surveillance strategies of hepatitic and cirrhotic patients for the early diagnosis of HCC are among the topics. We should have knowledge of the present way of HCC follow up from different countries. This matter will also be discussed in the Working Party Report on HCC in Bangkok in the year of 2002.
